BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1219 related articles for article (PubMed ID: 11231627)

  • 1. Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming.
    Wolfers J; Lozier A; Raposo G; Regnault A; Théry C; Masurier C; Flament C; Pouzieux S; Faure F; Tursz T; Angevin E; Amigorena S; Zitvogel L
    Nat Med; 2001 Mar; 7(3):297-303. PubMed ID: 11231627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The immunogenicity of dendritic cell-derived exosomes.
    Quah BJ; O'Neill HC
    Blood Cells Mol Dis; 2005; 35(2):94-110. PubMed ID: 15975838
    [TBL] [Abstract][Full Text] [Related]  

  • 3. No significant CTL cross-priming by dendritic cell-derived exosomes during murine lymphocytic choriomeningitis virus infection.
    Coppieters K; Barral AM; Juedes A; Wolfe T; Rodrigo E; Théry C; Amigorena S; von Herrath MG
    J Immunol; 2009 Feb; 182(4):2213-20. PubMed ID: 19201875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dendritic cell-derived exosomes stimulate stronger CD8+ CTL responses and antitumor immunity than tumor cell-derived exosomes.
    Hao S; Bai O; Yuan J; Qureshi M; Xiang J
    Cell Mol Immunol; 2006 Jun; 3(3):205-11. PubMed ID: 16893501
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dendritic cells fused with allogeneic colorectal cancer cell line present multiple colorectal cancer-specific antigens and induce antitumor immunity against autologous tumor cells.
    Koido S; Hara E; Homma S; Torii A; Toyama Y; Kawahara H; Watanabe M; Yanaga K; Fujise K; Tajiri H; Gong J; Toda G
    Clin Cancer Res; 2005 Nov; 11(21):7891-900. PubMed ID: 16278414
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonspecific CD4(+) T cells with uptake of antigen-specific dendritic cell-released exosomes stimulate antigen-specific CD8(+) CTL responses and long-term T cell memory.
    Hao S; Yuan J; Xiang J
    J Leukoc Biol; 2007 Oct; 82(4):829-38. PubMed ID: 17626150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Natural killer cells license dendritic cell cross-presentation of B lymphoma cell--associated antigens.
    Dao T; Gomez-Nunez M; Antczak C; Kappel B; Jaggi JS; Korontsvit T; Zakhaleva V; Scheinberg DA
    Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8763-72. PubMed ID: 16361564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Presentation of donor major histocompatibility complex antigens by bone marrow dendritic cell-derived exosomes modulates allograft rejection.
    Pêche H; Heslan M; Usal C; Amigorena S; Cuturi MC
    Transplantation; 2003 Nov; 76(10):1503-10. PubMed ID: 14657694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficient induction of antitumor T cell immunity by exosomes derived from heat-shocked lymphoma cells.
    Chen W; Wang J; Shao C; Liu S; Yu Y; Wang Q; Cao X
    Eur J Immunol; 2006 Jun; 36(6):1598-607. PubMed ID: 16708399
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Strategies for antigen loading of dendritic cells to enhance the antitumor immune response.
    Strome SE; Voss S; Wilcox R; Wakefield TL; Tamada K; Flies D; Chapoval A; Lu J; Kasperbauer JL; Padley D; Vile R; Gastineau D; Wettstein P; Chen L
    Cancer Res; 2002 Mar; 62(6):1884-9. PubMed ID: 11912169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. More efficient induction of HLA-A*0201-restricted and carcinoembryonic antigen (CEA)-specific CTL response by immunization with exosomes prepared from heat-stressed CEA-positive tumor cells.
    Dai S; Wan T; Wang B; Zhou X; Xiu F; Chen T; Wu Y; Cao X
    Clin Cancer Res; 2005 Oct; 11(20):7554-63. PubMed ID: 16243831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination.
    Galea-Lauri J; Wells JW; Darling D; Harrison P; Farzaneh F
    Cancer Immunol Immunother; 2004 Nov; 53(11):963-77. PubMed ID: 15146294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer immunotherapy using dendritic cell-derived exosomes.
    Amigorena S
    Medicina (B Aires); 2000; 60 Suppl 2():51-4. PubMed ID: 11188932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting heat shock proteins for immunotherapy in multiple myeloma: generation of myeloma-specific CTLs using dendritic cells pulsed with tumor-derived gp96.
    Qian J; Wang S; Yang J; Xie J; Lin P; Freeman ME; Yi Q
    Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8808-15. PubMed ID: 16361569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential capacity of chaperone-rich lysates in cross-presenting human endogenous and exogenous melanoma differentiation antigens.
    Bleifuss E; Bendz H; Sirch B; Thompson S; Brandl A; Milani V; Graner MW; Drexler I; Kuppner M; Katsanis E; Noessner E; Issels RD
    Int J Hyperthermia; 2008 Dec; 24(8):623-37. PubMed ID: 18608582
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mouse homologue of a novel human oncofetal antigen, glypican-3, evokes T-cell-mediated tumor rejection without autoimmune reactions in mice.
    Nakatsura T; Komori H; Kubo T; Yoshitake Y; Senju S; Katagiri T; Furukawa Y; Ogawa M; Nakamura Y; Nishimura Y
    Clin Cancer Res; 2004 Dec; 10(24):8630-40. PubMed ID: 15623647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Viral fusogenic membrane glycoproteins kill solid tumor cells by nonapoptotic mechanisms that promote cross presentation of tumor antigens by dendritic cells.
    Bateman AR; Harrington KJ; Kottke T; Ahmed A; Melcher AA; Gough MJ; Linardakis E; Riddle D; Dietz A; Lohse CM; Strome S; Peterson T; Simari R; Vile RG
    Cancer Res; 2002 Nov; 62(22):6566-78. PubMed ID: 12438252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor rejection by gene transfer of the MHC class II transactivator in murine mammary adenocarcinoma cells.
    Meazza R; Comes A; Orengo AM; Ferrini S; Accolla RS
    Eur J Immunol; 2003 May; 33(5):1183-92. PubMed ID: 12731043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Enhanced antitumor effects induced by lymphotactin gene-modified dendritic cells after pulsed with tumor antigen peptide].
    Zhang W; He L; Cao X
    Zhonghua Yi Xue Za Zhi; 1999 Mar; 79(3):170-3. PubMed ID: 11601032
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Augmentation of antitumor immune responses after adoptive transfer of bone marrow derived from donors immunized with tumor lysate-pulsed dendritic cells.
    Asavaroengchai W; Kotera Y; Koike N; Pilon-Thomas S; Mulé JJ
    Biol Blood Marrow Transplant; 2004 Aug; 10(8):524-33. PubMed ID: 15282530
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 61.